Nabriva Therapeutics plc - Ordinary Shares (NBRV) Social Stream
NABRIVA THERAPEUTICS PLC (NBRV) Price Targets From Analysts
Use the tables below to see what analysts covering NABRIVA THERAPEUTICS PLC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 3 | $4 | $1.35 | $2.675 | $1.46 | 83.22% |
| 2022-05-06 | 3 | $2 | $1.35 | $1.675 | $1.46 | 14.73% |
| 2022-08-04 | 2 | $50 | $50 | $50 | $1.46 | 3324.66% |
| 2022-09-16 | 2 | $18 | $18 | $18 | $1.46 | 1132.88% |
| 2022-11-11 | 2 | $8 | $8 | $8 | $1.46 | 447.95% |
| 2023-01-06 | 1 | $1 | $1 | $1 | $1.46 | -31.51% |
The Trend in the Analyst Price Target
NBRV's average price target has moved down $8 over the prior 23 months.
NBRV reports an average of 4,850.11% for its upside potential over the past 155 days.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-08-04 | 2 | 2 | 2 | 2 | 0.181 | 1004.97% |
| 2022-08-04 | 2 | 50 | 50 | 50 | 0.181 | 27524.31% |
| 2022-11-11 | 2 | 8 | 8 | 8 | 2.310 | 246.32% |
| 2023-01-06 | 2 | 1 | 1 | 1 | 1.300 | -23.08% |
| 2023-01-06 | 1 | 1 | 1 | 1 | 1.300 | -23.08% |
NBRV Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 5 | 0 | 0 | 0 | 1 | 1 | 1 |
The Trend in the Broker Recommendations
NBRV's average broker recommendation rating worsened by 2.33 over the prior 15 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for NBRV as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, NABRIVA THERAPEUTICS PLC's number of analysts covering the stock is higher than 31.96% of them.
- In terms of how NABRIVA THERAPEUTICS PLC fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than 7.61% of that group.
- NABRIVA THERAPEUTICS PLC's average analyst price target is higher than 95.01% of stocks in the mid market cap category.
- NBRV has a greater upside potential (average analyst target price relative to current price) than 474.7% of stocks in the mid market cap category.
In the Pharmaceutical Products industry, PTGX, XENE, and CMRX are the three stocks most similar to NABRIVA THERAPEUTICS PLC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is NBRV a Buy, Hold or Sell? See the POWR Ratings now!